• Home
  • Search Results
  • Obatoclax induces G1/G0-phase arrest via p38/p21(waf1/Cip1) signaling pathway in human esophageal cancer cells.

Obatoclax induces G1/G0-phase arrest via p38/p21(waf1/Cip1) signaling pathway in human esophageal cancer cells.

Journal of cellular biochemistry (2014-05-03)
Desheng Zhong, Chunping Gu, Lili Shi, Tianrong Xun, Xiaojuan Li, Shuwen Liu, Le Yu
ABSTRACT

Pan-Bcl-2 family inhibitor obatoclax has been demonstrated to be effective against various cancers, of which the mechanism of action is not fully understood. In this study, we demonstrate that obatoclax suppressed esophageal cancer cell viability with concomitant G1/G0-phase cell cycle arrest. At the tested concentrations (1/2 IC50 and IC50), obatoclax neither induced PARP cleavage nor increased the Annexin V-positive population, suggesting G1/G0-phase arrest rather than apoptosis accounts for most of the reduction of cell viability produced by obatoclax. Double knockdown of Bak and Bax by small interference RNA failed to block obatoclax-induced G1/G0-phase arrest, implying its role in cell cycle progression is Bak/Bax-independent. The cell cycle arresting effect of obatoclax was associated with up-regulation of p21(waf1/Cip1). Knockdown of p21(waf1/Cip1) significantly attenuated obatoclax-induced G1/G0-phase arrest. Although obatoclax stimulated phosphorylation of Erk, p38, and JNK, pharmacological inhibition of p38 but not Erk or JNK blocked obatoclax-induced G1/G0-phase arrest. Moreover, knockdown of p38 abolished the cell cycle arresting effect of obatoclax. In consistent with this finding, inhibition of p38 blocked obatoclax-induced p21(waf1/Cip1) expression while inhibition of Erk or JNK failed to exert similar effect. To conclude, these findings suggest that obatoclax induced cell cycle arrest via p38/p21(waf1/Cip1) signaling pathway. This study may shed a new light on the anti-cancer activity of obatoclax in relation to cell cycle arrest.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
MISSION® esiRNA, targeting human CDKN1A
Sigma-Aldrich
MISSION® esiRNA, targeting human SLC12A9
Sigma-Aldrich
MISSION® esiRNA, targeting human BAK1
Sigma-Aldrich
MISSION® esiRNA, targeting human NKX3-1
Sigma-Aldrich
MISSION® esiRNA, targeting human BAX
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Mapk14
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Slc12a9
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Cdkn1a
Sigma-Aldrich
MISSION® esiRNA, targeting human SYP
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Nkx3-1
Sigma-Aldrich
MISSION® esiRNA, targeting human MAPK14

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.